{"id":82844,"date":"2026-07-16T12:05:13","date_gmt":"2026-07-16T12:05:13","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/"},"modified":"2026-07-16T12:05:13","modified_gmt":"2026-07-16T12:05:13","slug":"umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/","title":{"rendered":"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies"},"content":{"rendered":"<div>\n<ul type=\"disc\">\n<li><em>The company\u2019s lead internal program expands its\u00a0<\/em>in vivo<em> CAR T clinical pipeline for patients with relapsed\/refractory B cell malignancies<\/em><\/li>\n<li><em>First patient expected to be dosed in Q3 2026<\/em>\n<\/li>\n<\/ul>\n<p>SEATTLE, July  16, 2026  (GLOBE NEWSWIRE) &#8212; Umoja Biopharma, Inc., a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) recently cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-directed <em>in vivo<\/em> CAR T cell therapy candidate for adults with relapsed\/refractory B cell malignancies.<\/p>\n<p>\u201cUB-VV400 is our second VivoVec&#x2122; based <em>in vivo<\/em> CAR T cell program to advance to U.S. clinical trials,\u201d said Luke Walker, M.D., Chief Medical Officer of Umoja Biopharma. \u201cGenerating CAR T cells within a patient\u2019s body would have the potential to transform clinical practice. We designed this Phase 1\/2 trial to address a critical, real-world unmet need for patients, including those who have progressed after prior CAR T cell treatment. We remain highly encouraged by the early clinical activity and safety profile seen in the patients treated in our investigator-initiated trial of UB-VV400, and we look forward to sharing initial clinical data.\u201d<\/p>\n<p>The Phase 1\/2 VIBRANT-1 study of UB-VV400 will open soon at U.S. clinical sites, with the first patient anticipated to be dosed in Q3 this year. The open-label, dose escalation and expansion trial is designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and preliminary antitumor activity of UB-VV400 in combination with rapamycin in patients with relapsed\/refractory B cell malignancies.<\/p>\n<p>Initial clinical data from the investigator-initiated trial of UB-VV400 in China is expected to be shared at a major medical meeting in the second half of 2026.<\/p>\n<p><strong>About Umoja Biopharma\u00a0<\/strong><br \/>Umoja Biopharma, Inc. is a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases. Umoja\u2019s VivoVec&#x2122;\u00a0<em>in vivo\u00a0<\/em>gene delivery technology empowers a patient\u2019s own immune system to fight disease. Enabling its core technology is the Company\u2019s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_00YpVfcxeNqFZFycKKBQUjV-60YeaL_8SEFtyMeAjavXnOha65GGK2ysTSoSfuhNiURN6cgvSpYqvGTcAqMhAjdThdcJrntyWC67INAbSGxKhH7GBwAdheoZI1QmjAN\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>\u00a0and visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w-0iCjcRThDDWHIeGIrnH-Hfv8sT1nQ54YjN1Ykk3L88dJ60RV7ry5j_fXWcI89qNSTY9VR4NUfQ_Quh25vCJli6XNYDf2O6orhk4rFOx0o=\" rel=\"nofollow\" target=\"_blank\" title=\"umoja-biopharma.com\">umoja-biopharma.com<\/a><strong>.<\/strong><\/p>\n<p><strong>Contacts:<\/strong><\/p>\n<p><strong>Investors<\/strong><br \/>Nate Hardy<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6OmxS-TtmOJ1yEN258G0WI9Gh4oOJddxHly7Lu4uK7xqvmebDZBFbi1_ocaJTCDAf02cTSvfVu8Csd4pv4U249VsVoh0iFF6RC3ddlmPQoqITs1WFuoxiKKIHGpAwNh4\" rel=\"nofollow\" target=\"_blank\" title=\"nate.hardy@umoja-biopharma.com\">nate.hardy@umoja-biopharma.com<\/a><\/p>\n<p><strong>Media<\/strong><br \/>Matt Wright<br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DfzQ-dn1pOrO2x-87e-1utT0Ug2b4-qp02Ms5OG0yV-x2vM4f2UNAzCyVWVDg6WTZ5r-4GS7kmQeDCeNPhjFcTXOnUQsVdO4zD_Rp0cNUVbKoHfXawf1X4VlyZhpF7sv\" rel=\"nofollow\" target=\"_blank\" title=\"media@umoja-biopharma.com\">media@umoja-biopharma.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDUxYjEyZjQtZTVjNS00YjE4LWFiZTEtNzllODU3YWE4ZTY0LTEyMjI0NTAtMjAyNi0wNy0xNi1lbg==\/tiny\/Umoja-Biopharma-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The company\u2019s lead internal program expands its\u00a0in vivo CAR T clinical pipeline for patients with relapsed\/refractory B cell malignancies First patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE NEWSWIRE) &#8212; Umoja Biopharma, Inc., a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-82844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies\" \/>\n<meta property=\"og:description\" content=\"The company\u2019s lead internal program expands its\u00a0in vivo CAR T clinical pipeline for patients with relapsed\/refractory B cell malignancies First pat\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T12:05:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies\",\"datePublished\":\"2026-07-16T12:05:13+00:00\",\"dateModified\":\"2026-07-16T12:05:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\"},\"wordCount\":433,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"People\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\",\"name\":\"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-07-16T12:05:13+00:00\",\"dateModified\":\"2026-07-16T12:05:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/","og_locale":"en_US","og_type":"article","og_title":"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies","og_description":"The company\u2019s lead internal program expands its\u00a0in vivo CAR T clinical pipeline for patients with relapsed\/refractory B cell malignancies First pat","og_url":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-07-16T12:05:13+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies","datePublished":"2026-07-16T12:05:13+00:00","dateModified":"2026-07-16T12:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/"},"wordCount":433,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["People"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/","url":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/","name":"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-07-16T12:05:13+00:00","dateModified":"2026-07-16T12:05:13+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry\u2019s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed\/Refractory B Cell Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/82844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=82844"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/82844\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=82844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=82844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=82844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}